Central α-adrenergic systems as targets for hypotensive drugs

  • Walter Kobinger
Part of the Reviews of Physiology, Biochemistry and Pharmacology book series (volume 81)


Sympathetic Nerve Activity Hypotensive Effect Splanchnic Nerve Hypotensive Action Hypotensive Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aars, H.: Effects of clonidine on aortic diameter and aortic baroreceptor activity: Eur. J. Pharmacol. 20, 52–59 (1972)Google Scholar
  2. Ahlquist, R.P.: Study of adrenotropic receptors. Am. J. Physiol. 153, 586–600 (1948)Google Scholar
  3. Alexander, R.S.: Tonic and reflex functions of medullary sympathetic cardiovascular centers. J. Neurophysiol. 9, 205–217 (1946)Google Scholar
  4. Andén, N.E., Corrodi, H., Fuxe, K., Hökfelt, T., Rydin, C., Svensson, T.: Evidence for a central noradrenaline receptor stimulation by clonidine. Life Sci. 9, 513–523 (1970)Google Scholar
  5. Andén, N.E., Dahlström, A., Fuxe, K., Larsson, K., Olson, L., Ungerstedt, U.: Ascending monoamine neurons to the telencephalon and diencephalon. Acta Physiol. Scand. 67, 313–326 (1966)Google Scholar
  6. Andén, N.E., Engel, J., Rubenson, A.: Mode of action of L-DOPA on central noradrenaline mechanism. Naunyn Schmiedebergs Arch. Pharmacol. 273, 1–10 (1972)Google Scholar
  7. Andén, N.E., Grabowska, M., Strömbom, U.: Different alpha-adrenoreceptors in the central nervous system mediating biochemical and functional effects of clonidine and receptor blocking agents. Naunyn Schmiedebergs Arch. Pharmacol. 292, 43–52 (1976)Google Scholar
  8. Antonaccio, M.J., Robson, R.D., Burrell, R.: Effects of clonidine on baroreceptor function in anaesthetized dogs. Eur. J. Pharmacol. 30, 6–14 (1975)Google Scholar
  9. Antonaccio, M.J., Robson, R.D., Kerwin, L.: Evidence for increased vagal tone and enhancement of baroreceptor reflex activity after xylazine (2-(2, 6-Dimethylphenyla-mino)-4-H-5, 6-dihydro-l, 3-thiazine) in anesthetized dogs. Eur. J.Pharmacol. 23, 311–315 (1973)Google Scholar
  10. Ariëns, E.J.: Medical Chemistry, Molecular Pharmacology. New York-London: Academic Press, Vol. I, p. 145/169Google Scholar
  11. Autret, A.M., Schmitt, H., Fénard, S., Péillot, N.: Comparison of haemodynamic effects of α-sympathomimetic drugs. Eur. J. Pharmacol. 13, 208–217 (1971)Google Scholar
  12. Baum, T., Shropshire, A.T.: Studies on the centrally mediated hypotensive activity of guanabenz. Eur. J. Pharmacol. 37, 31–44 (1976)Google Scholar
  13. Baum, T., Shropshire, A.T., Rowles, G., van Pelt, R., Fernandez, S.P., Eckfeld, D., Gluckmann, M.J.: General pharmacological actions of the antihypertensive agent 2, 6-dichlorbenzylidene aminoguanidine acetate (Wy-8678). J. Pharmacol. Exp. Ther. 171, 276–287 (1970)Google Scholar
  14. Baum, T., Shropshire, A.T., Varner, L.L.: Contribution of the central nervous system to the action of several antihypertensive agents (methyldopa, hydralazine and guanethi-dine). J. Pharmacol. Exp. Ther. 182, 135–144 (1972)Google Scholar
  15. Bentley, G.A., Li, D.M.F.: Studies of the new hypotensive effect of 2-(2, 6 dichlorpheny-lamino)-2-imidazoline hydrochloride (St 155, Catapresan). Eur. J. Pharmacol. 4, 124–134 (1968)Google Scholar
  16. Bock, K.D., Merguet, P., Heimsoth, V.H.: Effect of clonidine on regional blood flow and its use in the treatment of hypertension. In: Hypertension: Mechanisms and Management. Onesti, G., Kim, K.E., Moyer, J.H. (eds.) New York: Grune & Stratton 1973 pp. 395–403Google Scholar
  17. Bogaievsky, D., Bogaievsky, Y., Tsoucaris-Kupfer, D., Schmitt, D.: Blockade of the central hypotensive effect of clonidine by α-adrenoceptor antagonists in rats, rabbits and dogs. Clin. Exp. Pharmacol. Physiol. 1, 527–534 (1974)Google Scholar
  18. Boissier, J.R., Giudicelli, J.F., Fichelle, J., Schmitt, H., Schmitt, H.: Cardiovascular effects of 2-(2, 6-dichlorphenylamino)-2-imidazoline-hydrochloride (St 155). I. Peripheral sympathetic system. Eur. J. Pharmacol. 2, 333–339 (1968)Google Scholar
  19. Bolme, P., Corrodi, H., Fuxe, K.: Possible mechanisms of the hypotensive action of 2, 6-dichlorobenzylidene aminoguanidine: evidence for central noradrenaline receptor stimulation. Eur. J. Pharmacol. 23, 175–182 (1973)Google Scholar
  20. Bolme, P., Corrodi, H., Fuxe, K., Hökfelt, T., Lidbrink, P., Goldstein, M.: Possible involve-ment of central adrenaline neurons in vasomotor and respiratory control. Studies with clonidine and its interactions with piperoxan and yohimbine. Eur. J. Pharmacol. 28, 89–94 (1974)Google Scholar
  21. Bolme, P., Fuxe, K.: Pharmacological studies on the hypotensive effects of clonidine. Eur. J. Pharmacol. 13, 168–174 (1971)Google Scholar
  22. Bousquet, P., Guertzenstein, P.G.: Localization of the central cardiovascular action of clonidine. Br. J. Pharmacol. 49, 573–579 (1973)Google Scholar
  23. Boyajy, L.D., Manning, R., Mc.Intosh, R., Schaefer, F., Herzig, M., Schaaf, J., Trapold, J.H.: Cardiovascular effects of 2-(2, 6-dichlorphenyl)-5,6-dihydroimidazo-(2, 1-b)-thiazole hydrobromide (44-549). Volunteer Abstract No. 162. 5th Int. Congr. Pharmacol., San Francisco, 1972Google Scholar
  24. Braestrup, C.: Effects of phenoxybenzamine, aceperone and clonidine on the level of 3-methoxy-4-hydroxy-phenylglycol (MOPEG) in rat brain. J. Pharm. Pharmacol. 26, 139–141 (1974)Google Scholar
  25. Bream, J.H., Lauener, H., Picard, C.W., Scholtysik, G., White, T.G.: Substituted phenyl-acetylguanidines: anew class of antihypertensive agents. Arzneim. Forsch. 25, 1477–1482 (1975)Google Scholar
  26. Brugger, A., Salva, J.A., Sopena, M., Oliver, R.: Estudio experimental sobre el mecanismo de accion del clorhydrato de 2-(2, 6 diclorofenilamino)-2-imidazolina (St 155). Rev. Exp. Fisiol. 25, 233–237 (1969)Google Scholar
  27. Brunner, H., Hedwall, P.R., Maître, L., Meier, M.: Antihypertensive effects of alphamethy-lated catecholamine analogues in the rat. Br. J. Pharmacol. 30, 108–122 (1967)Google Scholar
  28. Butcher, L.L., Eastgate, S.M., Hodge, G.K.: Evidence that punctate intracerebral administration of 6-hydroxy-dopamine fails to produce selective neuronal degeneration. Comparison with copper sulfate and factors governing the deportment of fluids injected into brain. Naunyn Schmiedebergs Arch. Pharmacol. 285, 31–70 (1974)Google Scholar
  29. Carlsson, A., Lindquist, M.: In-vivo decarboxylation of α-methyl DOPA and α-methyl dopamine (3-hydroxytyramine). Acta Physiol. Scand. 54, 87–94 (1962)Google Scholar
  30. Chalmers, J.P., Reid, J.L.: Participation of central noradrenergic neurons in arterial baro-receptor reflexes in the rabbit. A study with intracisternally administered 6-hydroxy-dopamine. Circ. Res., 31, 789–804 (1972)Google Scholar
  31. Chamberlain, D.A., Howard, H.: Guanethidine and methyldopa: A haemodynamic study. Br. Heart J. 26, 528–536 (1964)Google Scholar
  32. Constantine, J.W., McShane, W.K.: Analysis of the cardiovascular effects of 2-(2, 6-dichlorphenylamino)-2-imidazoline hydrochloride (Catapres). Eur. J. Pharmacol. 4, 109–123 (1968)Google Scholar
  33. Cosnier, D., Duchene-Marullaz, P., Grimal, J., Rispat, G., Streichenberger, G.: Pharmacological properties of 2-(2-chloro-p-toluidino)-2-imidazoline-nitrate (tolonidine), a new antihypertensive agent. I Action on blood pressure and heart rate. Arzneim. Forsch. 25, 1557–1561 (1975a)Google Scholar
  34. Cosnier, D., Labrid, C., Rispat, G., Streichenberger, G.: Pharmacological properties of 2-(2-chloro-p-toluidino)-2-imidazoline-nitrate (tolonidine), a new antihypertensive agent. II Action on cardiac contraction, circulatory parameters, autonomic receptors and dimesis. Arzneim. Forsch. 25, 1802–1806 (1975b)Google Scholar
  35. Cottle, M.K.: Degeneration studies of primary afferents of IX th and Xth cranial nerves in the cat. J. Comp. Neurol. 122, 329–345 (1964)Google Scholar
  36. Coupar, J.M., Kirby, M.J.: The effect of clonidine on human isolated smooth muscle. Eur. J. Pharmacol. 17, 50–58 (1972)Google Scholar
  37. Crill, W.E., Reis, D.J.: Distribution of carotid sinus and depressor nerves in cat brain stem. Am. J. Physiol. 214, 269–276 (1968)Google Scholar
  38. Csongrady, A., Kobinger, W.: Investigations into the positive inotropic effect of clonidine in isolated hearts. Naunyn Schmiedebergs Arch. Pharmacol. 282, 123–128 (1974)Google Scholar
  39. Davies, D.S., Reid, J.L. (eds.): Central Action of Drugs in Blood Pressure Regulation. Tunbridge Wells: Pitman Medical Publishing (1975)Google Scholar
  40. Day, M.D., Rand, M.J.: Some observations on the pharmacology of α-methyldopa. Br. J. Pharmacol. 22, 72–86 (1964)Google Scholar
  41. Day, M.D., Roach, A.G., Withing, R.L.: The mechanism of the antihypertensive action of α-methyl-DOPA in hypertensive rats. Eur. J. Pharmacol. 21, 271–280 (1973)Google Scholar
  42. Deck, R., Oberdorf, A., Kroneberg, G.: Die Wirkung von 2-(2, 6-dichlorphenylamino)-2-imidazolin Hydrochlorid (Clonidin) auf die Kontraktion und die Acetylcholin-Frei-setzung am isolierten, koaxial elektrisch gereizten Meerschweinchenileum. Arzneim. Forsch. 21, 1580–1584 (1971)Google Scholar
  43. Dhawan, B.N., Johri, M.B., Singh, G.B., Srimal, R.C., Viswesaram, D.: Effect of clonidine on the excitability of vasomotor loci in the cat. Br. J. Pharmacol. 54, 17–21 (1975)Google Scholar
  44. Djawan, S., Mlczoch, J., Niederberger, M., Penner, E., Grabner, G.: Ein neues Antihyper-tensivum der Imidazolin-Reihe: 5-Fluor-2-methyl-2-imidazol-idinylidenbenzamin Monohydrochlorid (St 600, Flutonidin); II. Hämodynamische Untersuchungen in Ruhe und unter Belastung. Wien. Klin. Wochenschr. 88, 199–206 (1976)Google Scholar
  45. Doba, N., Reis, D.: Role of central and peripheral adrenergic mechanisms in neurogenic hypertension produced by brainstem lesions in rat. Circ. Res. 34, 293–301. (1974)Google Scholar
  46. Dollery, C.T., Davies, D.S., Draffan, G.H., Dargie, H.J., Dean, C.R., Reid, J.L., Clare, R.A., Murray, S.: Clinical pharmacology and pharmacokinetics of clonidine, Clin. Pharmacol. Ther. 19, 11–17 (1976)Google Scholar
  47. Dollery, C.T., Reid, J.L.: Central noradrenergic neurones and the cardiovascular actions of clonidine in the rabbit. Br. J. Pharmacol. 47, 206–216 (1973)Google Scholar
  48. Farnebo, L.O., Hamberger, B.: Drug-induced changes in the release of 3H-monoamines from field stimulated rat brain slices. Acta Physiol. Scand. [Suppl.] 371, 35–44 (1971)Google Scholar
  49. Farnebo, L.O., Hamberger, B.: Catecholamine release and receptors in brain slices. In: Frontiers in Catecholamine Research. Usdin, E., Snyder, S.H. (eds.). New York: Pergamon Press 1973, pp. 589–593Google Scholar
  50. Finch, L.: The cardiovascular effects of intraventricular clonidine and Bay 1470 in conscious hypertensive cats. Br. J. Pharmacol. 52, 333–338 (1974)Google Scholar
  51. Finch, L.: The central hypotensive action of clonidine and Bay 1470 in cats and rats. Clin. Sci. Mol. Med. 48, 273s–278s (1975)Google Scholar
  52. Finch, L., Haeusler, G.: Further evidence for a central hypotensive action of α-methyl-DOPA in both the rat and the cat. Br. J. Pharmacol. 47, 217–228 (1973)Google Scholar
  53. Finch, L., Hersom, A., Hicks, P.: Studies on the hypotensive action of α-methyldopa-mine. Br. J. Pharmacol. 54, 445–451 (1975)Google Scholar
  54. Folkow, B., Neil, E.: Circulation. New York-London-Toronto: Oxford U. Pr.Google Scholar
  55. Folkow, B., Nilsson, N.J., Yonce, L.R.: Effect of “diving” on cardiac output in ducks. Acta Physiol. Scand. 70, 347–361 (1967)Google Scholar
  56. Franz, D.N., Hare, B.D., Neumayr, R.J.: Reciprocal control of sympathetic preganglionic neurons by monoaminergic, bulbospinal pathways and a selective effect of clonidine. In: Recent Advances in Hypertension. Milliez, P., Safar, M. (eds.). Reims: Boehringer Ingelheim 1975, Vol. I. pp. 85–96Google Scholar
  57. Fuxe, K.: The distribution of monoamine terminals in the central nervous system. Acta Physiol. Scand. 64 (Suppl. 247) (1965)Google Scholar
  58. Fuxe, K., Hökfelt, T., Bolme, P., Goldstein, M., Johansson, O., Jonsson, G., Lidbrink, P., Ljungdahl, A., Sachs, Ch.: The topography of central catecholamine pathways in relation to their possible role in blood-pressure control. In: Central Action of Drugs in Blood Pressure Regulation. Davies, D.S., Reid, J.L. (eds.). Tunbridge Wells: Pitman Medical Publishing 1975, pp. 8–22Google Scholar
  59. Gagnon, D.J., Melville, K.I.: Possible dual role of noradrenaline in cardiovascular responses mediated by the central nervous system. Can. J. Physiol. Pharmacol. 46, 595–599 (1968)Google Scholar
  60. Gillespie, L., Jr., Oates, J.A., Crout, J.R., Sjoerdsma, A.: Clinical and chemical studies with α-methyl-dopa in patients with hypertension. Circulation 25, 281–291 (1962)Google Scholar
  61. Giudicelli, R., Beauvallet, M., Chabrier, P., Najer, H., Delépine, M.M.: Sur Faction vasculaire de quelques amino-2-oxazolines N-substituées. C. R. Acad. Sci. (Paris) 247, 2494–2497 (1958)Google Scholar
  62. Goldberg, L.J., Da Costa, F.M., Ozaki, M.: Actions of the decarboxylase inhibitor, α-methyl-3, 4-dihydroxyphenylolamine in the dog. Nature 188, 502–504 (1960)Google Scholar
  63. Grabner, G., Michalek, P., Pokorny, D., Vormittag, E.: Klinische und experimentelle Untersuchungen mit der neuen blutdrucksenkenden Substanz 2-(2, dichlorphenyl-amino)-2-imidazolinhydrochlorid. Arzneim. Forsch. 16, 1174–1179 (1966)Google Scholar
  64. Grabowska, M., Andén, N.E.: Noradrenaline synthesis and utilisation: Control by nerve impulse flow under normal conditions and after treatment with alpha-adrenoceptor blocking agents. Naunyn Schmiedebergs Arch. Pharmacol. 292, 53–58 (1976)Google Scholar
  65. Graubner, W., Wolf, M.: Kritische Betrachtungen zum Wirkungsmechanismus des 2-(2, 6-dichlorphenylamino)-2-imidazolinhydrochlorid. Arzneim. Forsch. 16, 1055–1058 (1966)Google Scholar
  66. Haeusler, G.: Activation of the central pathway of the baroreceptor reflex, a possible mechanism of the hypotensive action of clonidine. Naunyn Schmiedebergs Arch. Pharmacol. 278, 231–246 (1973)Google Scholar
  67. Haeusler, G.: Further similarities between the action of clonidine and a central activation of the depressor baroreceptor reflex. Naunyn Schmiedebergs Arch. Pharmacol. 285, 1–14 (1974a)Google Scholar
  68. Haeusler, G.: Clonidine induced inhibition of sympathetic nerve activity: no indication for a central presynaptic or an indirect sympathomimetic mode of action. Naunyn Schmiedebergs Arch. Pharmacol. 286, 97–111 (1974b)Google Scholar
  69. Haeusler, G.: Cardiovascular regulation by central adrenergic mechanisms and its alteration by hypotensive drugs. Circ. Res. 36/37 (Suppl. 1), 223–232 (1975)Google Scholar
  70. Haeusler, G.: Inhibition of the preganglionic sympathetic neurone through spinal α-adrenoceptors. Naunyn Schmiedebergs Arch. Pharmacol. 293, R 15 (1976)Google Scholar
  71. Haeusler, G., Finch, L.: On the nature of the central hypotensive effect of clonidine on alpha-methyldopa. Reunion Commune de la Deutsche Pharmakologische Gesellschaft et de l'Association Francaise des Pharmacologistes, Paris, 25–27 September 1972, Abstracts, pp. 16–17Google Scholar
  72. Haeusler, G., Lewis, P.: The baroreceptor reflex and its relations to central adrenergic mechanisms. In: Recent Advances in Hypertension. Milliez, P., Safar, M.(eds.). Reims: Boehringer Ingelheim 1975, pp. 17–26Google Scholar
  73. Hamperl, H., Heller, H.: Die Ausbreitung intracisternal injizierter Stoffe im Liquorraum. Naunyn Schmiedebergs Arch. Pharmacol. 173, 283–290 (1933)Google Scholar
  74. Heise, A., Kroneberg, G.: Alpha-sympathetic receptor stimulation in the brain and hypotensive action of α-methyl-DOPA. Eur. J. Pharmacol. 17, 315–317 (1972)Google Scholar
  75. Heise, A., Kroneberg, G., Schlossmann, K.: α-sympathicomimetische Eigenschaften als Ursache der blutdrucksteigernden und blutdrucksenkenden Wirkung von BAY 1470 (2-(2,6-xylidino)-5,6-dihydro-4H-l, 3-thiazinhydrochlorid). Naunyn Schmiedebergs Arch. Pharmacol. 268, 348–360 (1971)Google Scholar
  76. Heller, H.: Über die zentrale Blutdruckwirkung des Adrenalins, Naunyn Schmiedebergs Arch. Pharmacol. 173, 291–300 (1933)Google Scholar
  77. Henning, M.: Blood pressure and noradrenaline levels after treatment with α-methyldopa, α-methyldopamine and α-methyl-m-tyrosine. J. Pharm. Pharmacol. 19, 775–779 (1967)Google Scholar
  78. Henning, M.: Studies on the mode of action of α-methyldopa. Acta Physiol. Scand. (Suppl.) 322 1–37 (1969a)Google Scholar
  79. Henning, M.: Interaction of DOPA Decarboxylase Inhibitors with the effect of α-methyl-dopa on blood pressure and tissue monoamines in rats. Acta Pharmacol. Toxicol. 27, 135–148 (1969b)Google Scholar
  80. Henning, M., Rubenson, A.: Evidence that the hypotensive action of α-methyl-DOPA is mediated by central actions of methylnoradrenaline. J. Pharm. Pharmacol. 23, 407–411 (1971)Google Scholar
  81. Henning, M., Stock, G., Trolin, G.: Circulatory effects of clonidine after pre-hypotha-lamic section in the rat. Acta Pharmacol. Toxicol. 38, 376–381 (1976)Google Scholar
  82. Henning, M., van Zwieten, P.A.: Central hypotensive effect of α-methyl-DOPA. J. Pharm. Pharmacol. 19, 403–405 (1967)Google Scholar
  83. Henning, M., van Zwieten, P.A.: Central hypotensive action of α-methyl-DOPA. J. Pharm. Pharmacol. 20, 409–417 (1968)Google Scholar
  84. Heymans, C., Neil, E.: Reflexogenic Areas of the Cardiovascular System. London: Churchill 1958, p. 73Google Scholar
  85. Hoefke, W., Kobinger, W.: Pharmakologische Wirkung des 2-(2,6-dichlorphenylamino)-2-imidazolinhydrochlorids, einer neuen, antihypertensiven Substanz. Arzneim. Forsch. 16, 1038–1050 (1966)Google Scholar
  86. Höefke, W., Walland, A., Kobinger, W.: Relationship between activity and structure in derivatives of clonidine. Arzneim. Forsch. 25, 786–793 (1975)Google Scholar
  87. Höefke, W., Warnke-Sachs, E.: Influence of desmethylimipramine on the hypotensive effect of clonidine. Arzneim. Forsch. 24, 1046–1047 (1974)Google Scholar
  88. Hökfelt, T., Fuxe, K., Goldstein, M., Johansson, O.: Evidence for adrenaline neurons in the rat brain. Acta Physiol. Scand. 89, 286–288 (1973)Google Scholar
  89. Hökfelt, B., Hedeland, H., Dymling, J.-F.: Studies on catecholamines, renin and aldoste-rone following catapresan R (2-(2,6-dichlor-phenylamine)-2-imidazoline hydrochlor-ide) in hypertensive patients. Eur. J. Pharmacol. 10, 389–397 (1970)Google Scholar
  90. Hökfelt, B., Hedeland, H., Hansson, B.-G.: The effects of clonidine and penbutolol, respectively on catecholamines in blood and urine, plasma renin activity and urinary aldosterone in hypertensive patients. Arch. Int. Pharmacodyn. 213, 307–321 (1975)Google Scholar
  91. Holtz, P., Palm, D.: Brenzkatechinamine und andere sympathicomimetische Amine. Rev. Physiol. Biochem. Pharmacol. 58 (1966)Google Scholar
  92. Hoyer, J., van Zwieten, P.A.: The centrally induced fall in blood pressure after the infusion of amphetamine and related drugs into the vertebral artery of the cat. J. Pharm. Pharmacol. 23, 892–893 (1971)Google Scholar
  93. Hoyer, J., van Zwieten, P.A.: The central hypotensive action of amphetamine, ephedrine, phentermine, chlorphentermine and fenfluramine. J. Pharm. Pharmacol. 24, 452–458 (1972)Google Scholar
  94. Hukuhara, T., Jr., Otsuka, Y., Takeda, R., Sakai, F.: Die zentralen Wirkungen des 2-(2, 6-dichlorphenylamino)-2-imidazolin-hydrochlorids. Arzneim. Forsch. 18, 1147–1153 (1968)Google Scholar
  95. Humphrey, D.R.: Neuronal activity in the medulla oblongata of cat evoked by stimulation of the carotid sinus nerve. In: Baroreceptors and Hypertension, Proceedings of an Internat. Sympos. Held at Dayton, Ohio. Kezdi, P. (ed.). Oxford: Pergamon Press 1967, pp. 131–167Google Scholar
  96. Iggo, A., Vogt, M.: Preganglionic sympathetic activity in normal and in reserpine-treated cats. J. Physiol. (Lond.) 150, 114–133 (1960)Google Scholar
  97. Ingenito, A.J., Barrett, M., Procita, A.: Centrally mediated peripheral hypotensive effect of α-methyldopa. J. Pharmacol. Exp. Ther. 175, 593–599 (1970)Google Scholar
  98. Ito, A., Schanberg, S.M.: Maintenance of tonic vasomotor activity by alpha and beta adrenergic mechanisms in medullary cardiovascular centers. J. Pharmacol. Exp. Ther. 189, 392–404 (1974)Google Scholar
  99. Jacobs, F., Werner, U., Schumann, H.J.: Zum Mechanismus der antihypertensiven Wir-kung des Oxazolin-Derivates Bay a 6781. Arzneim. Forsch. 22, 1124–1126 (1972)Google Scholar
  100. Jaju, B.P., Tangri, K.K., Bhargava, K.P.: Central vasomotor effects of α-methyl-DOPA. Can. J. Physiol. Pharmacol. 44, 687–690 (1966)Google Scholar
  101. Jen, T., Dienel, B., Bowman, H., Petta, J., Helt, A., Loev, B.: Amidines. 2.A new class of antihypertensive agents. 1, 2, 3, 5-tetrahydroimidazo (2, 1-b) quinazolines. J. Med. Chem. 15, 727–731 (1972)Google Scholar
  102. Jen, T., van Hoeven, H., Groves, W., Mc Lean, R., Loev, B.: Amidines and related Compounds. 6. Studies on structure-activity relationship of antihypertensive and anti-secretary agents related to clonidine. J. Med. Chem. 18, 90–99 (1975)Google Scholar
  103. de Jong, W.: Noradrenaline: central inhibitory control of blood pressure and heart rate. Eur. J. Pharmacol. 29, 179–181 (1974)Google Scholar
  104. de Jong, W., Nijkamp, F.P., Bohus, B.: Role of noradrenaline and serotonin in the central control of blood pressure in normotensive and spontaneous by hypertensive rats. Arch. Int. Pharmacodyn. 213, 272–284 (1975)Google Scholar
  105. Julius, S., Esler, M. (eds.): The Nervous System in Arterial Hypertension. Springfield: Charles C. Thomas 1976Google Scholar
  106. Kaneko, Y., Mc Cubbin, J.W., Page, I.H.: Mechanism by which serotonin, norepinephrine and reserpine cause central vasomotor inhibition. Circ. Res. 8, 1228–1234 (1960)Google Scholar
  107. Karppanen, H.O., Westermann, E.: Increased production of cyclic AMP in gastric tissue by stimulation of histamine2 (H2)-receptors. Naunyn Schmiedebergs Arch. Pharmacol. 279, 83–87 (1973)Google Scholar
  108. Katie, F., Lavery, H., Lowe, R.D.: The central action of clonidine and its antagonism. Br. J. Pharmacol. 44, 779–787 (1972)Google Scholar
  109. Kho, T.L., Schalekamp, M.A.D.H., Zaal, G.A., Wester, A., Birkenhäger, W.H.: Comparison between the effects of St 600 and catapres. Arch. Int. Pharmacodyn. 214, 347–350 (1975)Google Scholar
  110. Kirkendall, W.M., Wilson, W.R.: Pharmacodynamics and clinical use of guanethidine, bretylium and methyldopa. Am. J. Cardiol. 9, 107–115 (1962)Google Scholar
  111. Klevans, L.R., Kepner, K., Kovacs, J.L.: Role of forebrain in clonidine-induced suppression of cardiovascular responses, Eur. J. Pharmacol. 24, 262–265 (1973)Google Scholar
  112. Klupp, H., Knappen, F., Otsuka, Y., Streller, J., Teichmann, H.: Effects of clonidine on central sympathetic tone. Eur. J. Pharmacol. 10, 225–229 (1970)Google Scholar
  113. Kobinger, W.: Über den Wirkungsmechanismus einer neuen antihypertensiven Substanz mit Imidazolinstruktur. Naunyn Schmiedebergs Arch. Pharmacol. 258, 48–58 (1967)Google Scholar
  114. Kobinger, W.: Pharmacologic basis of the cardiovascular actions of clonidine. In: Hypertension: Mechanisms and Management. Onesti, G., Kim, K.E., Moyer, J.H. (eds.). New York: Grune & Stratton 1973, pp. 369–380Google Scholar
  115. Kobinger, W.: Medicinal chemistry related to the central regulation of blood pressure. II. Pharmacological part. In: Medicinal Chemistry IV. Maas, J. (ed.). Amsterdam-Oxford-New York: Elsevier Scientific Publishing 1974, pp. 107–120Google Scholar
  116. Kobinger, W.: Central cardiovascular actions of clonidine. In: Davies, D., Reid, J.L.: Central Action of Drugs in Blood Pressure Regulation. Tunbridge Wells: Pitman Medical Publishing 1975, pp. 181–193Google Scholar
  117. Kobinger, W., Oda, M.: Effects of sympathetic blocking substances on the diving reflex of ducks. Eur. J. Pharmacol. 7, 289–295 (1969)Google Scholar
  118. Kobinger, W., Pichler, L.: Evidence for direct α-adrenoceptor stimulation of effector neurons in cardiovascular centers by clonidine, Eur. J. Pharmacol. 27, 151–154 (1974)Google Scholar
  119. Kobinger, W., Pichler, L.: The central modulatory effect of clonidine on the cardiode-pressor reflex after suppression of synthesis and storage of noradrenaline. Eur. J. Pharmacol. 30, 56–62 (1975a)Google Scholar
  120. Kobinger, W., Pichler, L.: Localization in the CNS of adrenoceptors which facilitate a car-dioinhibitory reflex. Naunyn Schmiedebergs Arch. Pharmacol. 286, 371–377 (1975b)Google Scholar
  121. Kobinger, W., Pichler, L.: Investigation into some imidazoline compounds, with respect to peripheral α-adrenoceptor stimulation and depression of cardiovascular centers. Naunyn Schmiedebergs Arch. Pharmacol. 291, 175–191 (1975c)Google Scholar
  122. Kobinger, W., Pichler, L.: Centrally induced reduction in sympathetic tone-a postsynaptic α-adrenoceptor stimulating action of imidazolines. Eur. J. Pharmacol. 40, 311–320 (1976)Google Scholar
  123. Kobinger, W., Pichler, L.: Pharmacological characterization of B-HT 933 (2-Amino-6-ethyl-4, 5, 7, 8-tetrahydro-6H-oxazolo-|5, 4-d| azepin-dihydrochloride) as a hypotensive agent of the “Clonidine-Type”. Naunyn Schmiedebergs Arch. Pharmacol. 300, 39–46 (1977)Google Scholar
  124. Kobinger, W., Walland, A.: Kreislaufuntersuchungen mit 2-(2, 6-dichlorphenylamino)-2-imidazolinhydrochloride. Arzneim. Forsch. 17, 292–300 (1967a)Google Scholar
  125. Kobinger, W., Walland, A.: Investigations into the mechanism of the hypotensive effect of 2-(2, 6 dichlorphenylarnino)-2-imidazoline HC1. Eur. J. Pharmacol. 2, 155–162 (1967b)Google Scholar
  126. Kobinger, W., Walland, A.: Involvement of adrenergic receptors in central vagus activity. Eur. J. Pharmacol. 16, 120–122 (1971)Google Scholar
  127. Kobinger, W., Walland, A.: Evidence for a central activation of a vagal cardiodepressor reflex by clonidine. Eur. J. Pharmacol. 19, 203–209 (1972a)Google Scholar
  128. Kobinger, W., Walland, A.: Facilitation of vagal reflex bradycardia by an action of clonidine on central α-receptors. Eur. J. Pharmacol. 19, 210–217 (1972b)Google Scholar
  129. Kobinger, W., Walland, A.: Modulating effect of central adrenergic neurones on a vagally mediated cardioinhibitory reflex. Eur. J. Pharmacol. 22, 344–350 (1973)Google Scholar
  130. Korner, P.J.: Integrative neural cardiovascular control. Physiological Rev., 51 312–367 (1971)Google Scholar
  131. Korner, P.J., Blomberg, P.A., Bobik, A., Tonkin, A.M., Uther, J.B.: Valsalva constrictor reflex in human hypertension and after beta-adrenoceptor blockade in conscious rabbits. Clin. Sci. Mol. Med. (in press) (1976)Google Scholar
  132. Korner, P.J., Oliver, J.R., Sleight, P., Chalmers, J.P., Robinson, J.S.: Effects of clonidine on the baroreceptor-heart rate reflex and on single aortic baroreceptor fibre discharge. Eur. J. Pharmacol. 28, 189–198 (1974)Google Scholar
  133. Kroneberg, H.G.: Pharmakologie der blutdrucksenkenden Arzneimittel. Verh. Dtsch. Ges. Kreislaufforsch. 28/29 172–184 (1962/63)Google Scholar
  134. Kroneberg, G., Oberdorf, A., Hoffmeister, F., Wirth, W.: Zur Pharmakologie von 2-(2, 6-dimethylphenylamino)-4H-5, 6-dihydro-l, 3-thiazin (Bayer 1470), eines Hemmstof-fes adrenergischer und cholinergischer Neurone, Naunyn Schmiedebergs Arch. Pharmacol. 256, 257–280 (1967)Google Scholar
  135. Kündig, H., Monnier, H., Levin, N.W., Charlton, R.W.: Mechanism of action of St 155 on the blood pressure in rats. Arzneim. Forsch. 17, 1440–1444 (1967)Google Scholar
  136. Langer, S.Z., Enero, M.A., Adler-Graschinsky, W., Dubocovich, M.L., Celuchi, S.M.: Pre-synaptic regulatory mechanisme for noradrenaline release by nerve stimulation. In: Central Action of Drugs in Blood Pressure Regulations, Davies, D., Reid, J.L. (eds.). Tunbridge Wells: Pitman Medical Publishing 1975, pp. 133–150Google Scholar
  137. Laubie, M., Schmitt, H.: Effects hemodynamiques du St 155, 2-(2, 6-dichlorophenyla-mino)-2-imidazoline hydrochloride, chez le chien hypertendu. Arch. Int. Pharma-codyn. 179, 23–35 (1969)Google Scholar
  138. Li, D.M.P., Bentley, G.A.: The effect of St 155 on the active reflex vasodilatation induced by adrenaline, noradrenaline and veratrine. Eur. J. Pharmacol. 8, 39–46 (1969)Google Scholar
  139. Li, D.M.P., Bentley, G.A.: The effect of various antihypertensive drugs on the reflex responses to vasoactive substances. Eur. J. Pharmacol. 12, 24–34 (1970)Google Scholar
  140. Lindner, E., Kaiser, J.: Thiamenidine(Hoe 440), a new antihypertensive substance. Arch. Int. Pharmacodyn. 211, 305–325 (1974)Google Scholar
  141. Lipsky, J., Mc Allen, R.M., Spyer, K.M.: The sinus nerve and baroreceptor input to the medulla of the cat. J. Physiol. (Lond.) 251, 61–78 (1975)Google Scholar
  142. Löfwing, B.: Cardiovascular adjustments induced from the rostral cingulate gyrus. With special reference to sympathoinhibitory mechansims. Act Physiol. Scand. 53, (Suppl. 184) 1–82 (1961)Google Scholar
  143. Loeschcke, H.H., Koepchen, H.P.: Versuch zur Lokalisation des Angriffsortes der Atem und Kreislaufwirkung von Novocain im Liquor cerebrospinalis. Pflüegers Arch. 266, 628–641 (1958)Google Scholar
  144. Maling, H.M., Cho, A.K., Horakova, Z., Williams, M.A.: The pharmacologic effects of St 155 (Catapres) and related imidazolines in the rat. Pharmacology 2, 337–351 (1969)Google Scholar
  145. Maxwell, G.M.: The effects of 2-(2, 6-dichlorphenylamino)-2-imidazoline hydrochloride (catapres) upon the systemic and coronary haemodynamics and metabolism of intact dogs. Arch. Int. Pharmacodyn. 181, 7–14 (1969)Google Scholar
  146. McCall, R.B., Gebber, G.L.: Differential effect of baroreceptor reflexes and clonidine on frequency components of sympathetic discharge. Eur. J. Pharmacol. 36, 69–78 (1976)Google Scholar
  147. McCubbin, J.W., Kaneko, Y., Page, I.H.: Ability of serotonin and norepinephrine to mimic the central effects of reserpine on vasomotor activity. Circ. Res. 8. 849–858 (1960)Google Scholar
  148. Meerman-van Benthem, C.M., van der Meer, K., Mulden, J.J.C., Timmermans, P.B.M.W.M., van Zwieten, P.A.: Clonidine base: evidence for conjugation of both ring systems. Mol. Pharmacol. 11, 667–670 (1975)Google Scholar
  149. Merguet, P., Bock, K.D.: Effects of antihypertensive agents on skin and muscle blood flow in man. In: Hypertension: Mechanism and Management. Onesti, G., Kim, K.E., Moyer, J.E. (eds.). New York-London: Grune & Stratton, 1973, pp. 241–250Google Scholar
  150. Milliez, P., Safar, M. (eds.): Recent Advances in Hypertension. Monaco 1975. Reims: Boehringer Ingelheim 1975Google Scholar
  151. Muir, A.L., Burton, J.L., Lawrie, D.M.: Circulatory effects at rest and exercise of clonidine, an imidazoline derivative with hypertensive properties. Lancet 1969/II, 181–184Google Scholar
  152. Mujic, M., van Rossum, J.M.: Comparative pharmacodynamics of sympathomimetic imidazolines; studies on intestinal smooth muscle of the rabbit and the cardiovascular system of the cat. Arch. Int. Pharmacodyn. 155, 432–449 (1965)Google Scholar
  153. Muscholl, E.: Autonomic nervous system: Newer mechanisms of adrenergic blockade. Annu. Rev. Pharmacol. 6, 107–128 (1966)Google Scholar
  154. Muscholl, E., Maitre, L.: Release by sympathetic stimulation of α-methylnoradrenaline stored in the heart after administration of α-methyldopa. Experientia (Basel) 19, 658–659 (1963)Google Scholar
  155. Muscholl, E., Rahn, K.H.: Über den Nachweis und die Bedeutung von α-Methylnoradrenalin im Harn von Hypertonikern bei Verabreichung von α-Methyldopa. Pharmacol. Clin, 1, 19–20 (1968)Google Scholar
  156. Nayler, W.G., Price, J.M., Stone, J., Lowe, T.E.: Further observations on the cardiovascular effects of St 155 (Catapres). J. Pharmacol. Exp. Ther. 166, 364–373 (1969)Google Scholar
  157. Nayler, W.G., Price, J.M., Swann, J.B., Mc Innes, J., Race, D., Lowe, T.E.: Effect of the hypotensive drug St 155 (Catapres) on the heart and peripheral circulation. J. Pharmacol. Exp. Ther. 164, 45–59 (1968)Google Scholar
  158. Nayler, W.G., Rosenbaum, M., Mc Innes, J., Lowe, T.E.: Effect of a new hypotensive drug, St 155, on the systemic circulation. Am. Heart J. 72, 764–770 (1966)Google Scholar
  159. Nayler, W.G., Stone, J.: An effect of St 155 (clonidine), 2-(2, 6-dichlorphenylamino)-2-imidazoline hydrochloride, catapres on relationship between blood pressure and heart rate in dogs. Eur. J. Pharmacol. 10, 161–167 (1970)Google Scholar
  160. Nolan, P.L., Bentley, G.A.: Studies on orthostatic cardiovascular responses in anaesthetized cats. Clin. exp. Pharmacol. Physiol. (Suppl.) 2, 213–216 (1975)Google Scholar
  161. Oates, J.A., Gillespie, L., Udenfriend, S., Sjoerdsma, A.: Decarboxylase inhibition and blood pressure reduction by α-methyl-3, 4-dihydroxy-DL-phenylalanine. Science 131, 1890–1891 (1960)Google Scholar
  162. Onesti G., Fernandes, M., Kim, K.E. (eds.).: Regulation of Blood Pressure by the Central Nervous System. New York-San Francisco-London: Grune & Stratton 1976Google Scholar
  163. Onesti, G., Schwartz, A.B., Kim, K.E., Paz-Martinez, V., Swartz, CH.: Antihypertensive effect of clonidine. Circ. Res. 28 (Suppl. 2), 53–69 (1971)Google Scholar
  164. Onesti, G., Schwartz, A.B., Kim, K.E., Swartz, Ch., Brest, A.N.: Pharmacodynamic effects of a new antihypertensive drug, catapres (St 155). Circulation 39, 219–228 (1969)Google Scholar
  165. Paton, W.D.M., Vizi, E.S.: The inhibitory action of noradrenaline and adrenaline on acetyl-choline output by guinea-pig ileum longitudinal muscle strip. Br. J. Pharmacol. 35, 10–28 (1969)Google Scholar
  166. Pettinger, W., Horwitz, D., Spector, S., Sjoerdsma, A.: Enhancement by methyldopa of tyramine sensitivity in man. Nature 200, 1107–1108 (1963)Google Scholar
  167. Phillippu, A., Demmeler, R., Roensberg, G.: Effects of centrally applied drugs on pressure responses to hypothalamic stimulation. Naunyn Schmiedebergs Arch. Pharmacol. 287, 389–400 (1974)Google Scholar
  168. Philippu, A., Heyd, G., Burger, A.: Release of noradrenaline from the hypothalamus in vivo. Eur. J. Pharmacol. 9, 52–58 (1970)Google Scholar
  169. Phillippu, A., Przuntek, H., Heyd, G., Burger, A.: Central effects of sympathomimetic amines on the blood pressure. Eur. J. Pharmacol. 15, 200–208 (1971)Google Scholar
  170. Philippu, A., Roensberg, W., Przuntek, H.: Effects of adrenergic drugs on pressure responses to hypothalamic stimulation. Naunyn Schmiedebergs Arch. Pharmacol. 278, 373–386 (1973)Google Scholar
  171. Pletscher, A.H., Besendorf, H., Bächtold, H.P.: Benzo-a-chinolizine, eine neue Körper-klasse mit Wirkung auf den 5-Hydroxytryptamin — und Noradrenalin-Stoffwechsel des Gehirns. Naunyn Schmiedebergs Arch. Pharmacol. 232, 499–506 (1958)Google Scholar
  172. Pletscher, A., Gey, F.: The effect of a new decarboxylase inhibitor on endogenous and exogenous monoamines. Biochem. Pharmacol. 12, 223–228 (1963)Google Scholar
  173. Pook, K.H., Stähle, H., Daniel, H.: Strukturuntersuchungen an 2-(Arylimino) imidazoli-dinen und 2-(Arylamino) imidazolinen mit Hilfe der Protonen-und Kohlenstoff-13-Resonanz. Chem. Ber. 107, 2644–2657 (1974)Google Scholar
  174. Porter, C.C., Totaro, J.A., Leiby, C.M.: Some biochemical effects of α-methyl-3, 4-dihy-droxyphenylalanine and related compounds in mice. J. Pharmacol. Exp. Ther. 134, 139–145 (1961)Google Scholar
  175. Porter, C.C., Watson, L.S., Titus, D.C., Totaro, J.A., Byer, S.S.: Inhibition of DOPA decarboxylase by the hydrazino analogue of α-methyl-DOPA. Biochem. Pharmacol. 11, 1067–1077 (1962)Google Scholar
  176. Pullmann, B., Coubeils, J.L., Courriere, Ph., Gervois, J.P.: Quantum mechanical study of the conformational properties of phenethylamines of biochemical and medicinal interest. J. Med. Chem. 15, 17–23 (1972)Google Scholar
  177. Rand, M.J., Mc Culloch, M.W., Story, D.F.: Pre-junctional modulation of noradrenergic transmission by noradrenaline, dopamine and acetylcholine. In: Central Action of Drugs in Blood Pressure Regulation. Davies, D., Reid, J.L. (eds.). Tunbridge Wells: Pitman Medical Publishing 1975, pp. 94–132Google Scholar
  178. Rand, M.J., Wilson, J.: Mechanisms of the pressor and depressor actions of St 1 55 (2-(2, 6-dichlorphenylamino)-2-imidazoline-hydrochloride, Catapresan). Eur. J. Pharmacol. 3, 27–33 (1968)Google Scholar
  179. Reid, J.L., Briant, R.H., Dollery, C.T.: Desmethylimipramine and the hypotensive action of clonidine in the rabbit. Life Sci. 12, 459–467 (1973)Google Scholar
  180. Reid, J.L., Wing, L.M.H., Mathias, C.J., Frankel, H.L.: The central hypotensive action of clonidine in man: Studies in subjects with traumatic cervical spinal cord transection. Abstract of Paper Presented at the Eur. Soc. of Clinical Investigation, Rotterdam, 1976Google Scholar
  181. Robson, R.D., Kaplan, H.R.: An involvement of St 155 (2-(2, 6-dichlorphenylamino)-2-imidazoline hydrochloride, Catapres) in cholinergic mechanisms. Eur. J. Pharmacol. 5, 328–337 (1969)Google Scholar
  182. Robson, R.D., Kaplan, H.R., Laforce, S.: An investigation into the bradycardiac effects of St 155 (2-(2, 6-dichlorphenylamino)-2-imidazoline HC1 in the anaesthetised dog. J. Pharmacol. Exp. Ther. 169, 120–131 (1969)Google Scholar
  183. Rochette, L., Bralet, J.: Effect of clonidine on the synthesis of central dopamine. Biochem. Pharmacol. 24, 303–305 (1975)Google Scholar
  184. van Rossum, J.M.: Different types of sympathomimetic a-receptors. J. Pharm. Pharmacol. 17, 202–216 (1965)Google Scholar
  185. Rouot, B., Leclerc, G., Wermuth, C.-G.: Structure de la clonidine. Chim. Ther. 5, 545–551, (1973)Google Scholar
  186. Rouot, B., Leclerc, G., Wermuth, C.-G., Miesch, F., Schwartz, J.: Clonidine and related analogues. Quantitative correlations. J. Med. Chem. (in press) (1976)Google Scholar
  187. Rubenson, A.: Further studies on the mechanism of the central hypotensive effect of α-dopa, dl-in-tyrosine and 1-α-methyldopa. J. Pharm. Pharmacol. 23, 228–230 (1971a)Google Scholar
  188. Rubenson, A.: Analysis of the action of m-tyrosine on blood pressure in the conscious rat: evidence for a central hypotensive effect. J. Pharm. Pharmacol. 23, 412–419 (1971b)Google Scholar
  189. Saameli, K., Scholtysik, G., Waite, R.: Pharmacology of BS 100-141, a centrally acting antihypertensive drug. Clin. exper. Pharmacol. Physiol. (Suppl.) 2, 207–212 (1975)Google Scholar
  190. Sannerstedt, R., Conway, J.: Hemodynamic and vascular responses to antihypertensive treatment with adrenergic blocking agents: a review. Am. Heart J., 79, 122–127 (1970)Google Scholar
  191. Sattler, R.W., van Zwieten, P.A.: Acute hypotensive action of 2-(2, 6-dichlorphenylami-no)-2-imidazoline hydrochloride (St 155) after infusion into the cat's vertebral artery. Eur. J. Pharmacol. 2, 9–13 (1967)Google Scholar
  192. Schmitt, H.: Actions des alpha-sympathomimétiques sur les structures nerveuses. Actual. Pharmacol. (Paris) 24, 93–113 (1971)Google Scholar
  193. Schmitt, H.: On some unexplained effects of clonidine. In: Recent Advances in Hyperten-sion. Milliez, P., Safar, M. (eds.). Reims: Boehringer Ingelheim 1975, Vol. II, pp. 63–72Google Scholar
  194. Schmitt, H., Fénard, S.: Effets des substances sympathomimétiques sur les centres vaso-moteurs. Arch. Int. Pharmacodyn. 190, 229–240 (1971)Google Scholar
  195. Schmitt, H., Fournadjiev, G., Schmitt, H.: Central and peripheral effects of 2-(2, 6-dime-thylphenylamino)-4-H-5, 6-dihydro-l, 3-thiazin (Bayer 1470) on the sympathetic system. Eur. J. Pharmacol. 10, 230–238 (1970)Google Scholar
  196. Schmitt, H., Schmitt, H.: Localization of the hypotensive effect of 2-(2, 6-dichlorpheny-lamino)-2-imidazoline hydrochloride (St 155, Catapresan). Eur. J. Pharmacol. 6, 8–12 (1969)Google Scholar
  197. Schmitt, H., Schmitt, H.: Interactions between 2-(2, 6-dichlorophenylamino)-2-imidazo-line hydrochloride (St 155, catapresan R) and α-adrenergic blocking drugs. Eur. J. Pharmacol. 9, 7–13 (1970)Google Scholar
  198. Schmitt, H., Schmitt, H., Boissier, J.R., Giudicelli, J.F.: Centrally mediated decrease in sympathetic tone induced by 2-(2, 6-dichlorphenylamino)-2-imidazoline (St 155, Catapresan). Eur. J. Pharmacol. 2, 147–148 (1967)Google Scholar
  199. Schmitt, H., Schmitt, H., Boissier, J.R., Guidicelli, J.F., Fichelle, J.: Cardiovascular effects of 2-(2, 6-dichlorphenylamino)-2-imidazoline hydrochloride (St 155). II. Central sympathetic structures. Eur. J. Pharmacol. 2, 340 (1968)Google Scholar
  200. Schmitt, H., Schmitt, H., Fenard, S.: Evidence for an α-sympathomimetic component in the effects of catapresan on vasomotor centres: antagonism by piperoxane. Eur. J. Pharmacol. 14, 98–100 (1971)Google Scholar
  201. Schmitt, H., Schmitt, H., Fenard, S.: Decrease in the sympatho-inhibitory action of clonidine after destruction of the sympatho-inhibitory area. Experientia 29, 1247–1249 (1973a)Google Scholar
  202. Schmitt, H., Schmitt, H., Fenard, S.: Action of α-adrenergic blocking drugs on the sympathetic centres and their interactions with the central sympatho-inhibitory effect of clonidine. Arzneim. Forsch. 23, 40–45 (1973b)Google Scholar
  203. Schmitt, H., Schmitt, H., Fenard, S.: A technique for recording sympathetic nerve activity in unanaesthetized dogs. Neuropharmacology 13, 347–351 (1974)Google Scholar
  204. Scholtysik, G., Lauener, H., Eichenberger, E., Bürki, H., Salzmann, R., Müller-Schweinitzer, E., Waite, R.: Pharmacological actions of the antihypertensive agent N-amino-2-(-2, 6-dichlorphenyl) acetamide hydrochloride (BS 100-141). Arzneim. Forsch. 25, 1483–1491 (1975)Google Scholar
  205. Schwartz, A., Banach, S., Smith, J.S., Kim, K.E., Onesti, G., Swartz, Ch.: Clinical efficacy of clonidine in hypertension. In: Hypertension; Mechanisms and Management. Onesti, G., Kim, K.E., Moyer, J.H. (eds.). New York: Grune & Stratton 1973, pp. 389–394Google Scholar
  206. Scriabine, A., Stavorski, J., Wenger, H.C., Torchiana, M.L., Stone, C.A.: Cardiac slowing effects of clonidine (St 155) in dogs. J. Pharmacol. Exp. Ther. 171, 256–264 (1970)Google Scholar
  207. Seller, H., Illert, M.: The localization of the first synapse in the carotid sinus barorecep-tor reflex pathway and its alteration of the afferent input. Pflüegers Arch. 306, 1–19 (1969)Google Scholar
  208. Shaw, J., Hunyor, S.N., Korner, P.J.: Sites of central nervous action of clonidine on reflex autonomic function in the unanaesthetized rabbit. Eur. J. Pharmacol. 15, 66–78 (1971)Google Scholar
  209. Sherman, G.P., Grega, G.J., Woods, R.J., Buckley, J.P.: Evidence for a central hypotensive mechanism of 2-(2,6-dichlorphenylamino)-2-imidazoline (Catapresan, St 155). Eur. J. Pharmacol. 2, 326–328 (1969)Google Scholar
  210. Sinha, J.N., Atkinson, J.M., Schmitt, H.: Effects of clonidine and 1-DOPA on spontaneous and evoked splanchnic nerve discharges. Eur. J. Pharmacol. 24, 113–119 (1973)Google Scholar
  211. Sinha, J.N., Schmitt, H.: Central sympatho-inhibitory effects of intracisternal and intravenous administrations of noradrenaline in high doses. Eur. J. Pharmacol. 28 217–221 (1974)Google Scholar
  212. Sjoerdsma, A.: The central action of α-methyldopa and clonidine. In: Central Action of Drugs in Blood Pressure Regulation. Davies, D., Reid, J.L.. (eds.). Tunbridge Wells: Pitman Medical Publishing 1975, pp. 154–156Google Scholar
  213. Stähle, H.: See patent application, C.H. Boehringer Sohn, Chem. Abstr. 64, 2096e (1966)Google Scholar
  214. Stähle, H.: Medicinal chemistry related to the central regulation of blood pressure. I. Chemical part. In: Medicinal Chemistry IV. Maas, J. (ed.). Amsterdam-Oxford-New York: Elsevier Scientific Publishing 1974, pp. 75–105Google Scholar
  215. Stähle, H., Pook, K.-H.: Synthesen in der 2-Amino-imidazolin-Reihe. Liebigs Ann. Chem. 751, 159–167 (1971)Google Scholar
  216. Stähle, H., Pook, K.-H.: 55th Chem. Conference of the Chem. Inst. of Canada, Université Laval, Quebec, 1972Google Scholar
  217. Starke, K.: Alpha sympathomimetic inhibition of adrenergic and cholinergic transmission in the rabbit heart. Naunyn Schmiedebergs Arch. Pharmacol. 274, 18–45 (1972)Google Scholar
  218. Starke, K.: Regulation of noradrenaline release by presynaptic receptor systems. Rev. Physiol. Biochem. Pharmacol. 77, 1–124 (1977)Google Scholar
  219. Starke, K., Endo, T., Taube, H.D.: Relative pre-and post-synaptic potencies of α-adreno-ceptor agonists in the rabbit pulmonary artery. Nauyn Schmiedebergs Arch. Pharmacol. 291, 55–78 (1975)Google Scholar
  220. Starke, K., Montel, H.: Involvement of alpha-receptors in clonidine-induced inhibition of transmitter release from central monoamine neurones. Neuropharmacology 12, 1073–1080 (1973)Google Scholar
  221. Starke, K., Montel, H., Gayk, W., Merker, R.: Comparison of the effects of clonidine on pre-and postsynaptic adrenoceptors in the rabbit pulmonary artery. Naunyn Schmiedebergs Arch. Pharmacol. 285, 133–150 (1974)Google Scholar
  222. Starke, K., Schumann, H.J.: Zur peripheren sympathicus-hemmenden Wirkung des Cloni-dins. Experientia 27, 70–71 (1971)Google Scholar
  223. Starke, K., Wagner, J., Schümann, H.J.: Adrenergic neuron blockade by clonidine: comparison with guanethidine and local anaesthetics. Arch. Int. Pharmacodyn. 195, 291–308 (1972)Google Scholar
  224. Stjärne, L.: Clonidine enhances the secretion of sympathetic neurotransmitter from isolated guinea-pig tissues. Acta Physiol. Scand. 93, 142 (1975)Google Scholar
  225. Strömbom, U.: Catecholamine receptor agonists. Effects on motor activity and rate of tyrosine hydroxylation in mouse brain. Nauyn Schmiedebergs Arch. Pharmacol. 292, 167–176 (1976)Google Scholar
  226. Struyker Boudier, H.A.J.: Catecholamine receptors in nervous tissue. Relevance of neuro-nal catecholamine receptors in the mode of action of dopaminergic and antihyper-tensive drugs. Thesis, Nijmegen: Stichting Studentenpers., 1975Google Scholar
  227. Struyker Boudier, H.A.J., de Boer, J., Smeets, G., Lien, E.J., van Rossum, J.: Structure activity relationship for central and peripheral alpha adrenergic activities of imidazo-line derivatives. Life Sci. 17, 377–386 (1975a)Google Scholar
  228. Struyker Boudier, H., van Rossum, J.M.: Clonidine-induced cardiovascular effects after stereotaxic application in the hypothalamus of rats. J. Pharm. Pharmacol. 24, 410–411 (1972)Google Scholar
  229. Struyker Boudier, H.A.J., van Rossum, J.M., De Schaepdryver, A.F. (eds.): Essays on blood pressure control. Proceedings of an International Symposium on Hypertension, Nijmegen, 1974. Published by the Arch. Int. Pharmacodyn. (1975b)Google Scholar
  230. Struyker Boudier, H.A.J., Smeets, G.W.M., Brower, G.M., van Rossum, J.M.: Hypothala-mic alpha adrenergic receptors in cardiovascular regulation. Neuropharmacology 13, 837–846 (1974a)Google Scholar
  231. Struyker Boudier, H.A.J., Smeets, G.W.M., Brower, G.M., van Rossum, J.M.: Central and peripheral alpha adrenergic activity of imidazoline derivatives. Life Sci. 15, 887–899 (1974b)Google Scholar
  232. Svensson, T.H., Bunney, B.S., Aghajanian, G.K.: Inhibition of both noradrenergic and serotonergic neurons in brain by the α-adrenergic agonist clonidine. Brain Res., 92, 291–306 (1975)Google Scholar
  233. Tauberger, G., Kuhn, P.: Untersuchungen der zentralnerv ösen sympathicusdämpfenden Wirkungen von α-Methyl-dopa. Naunyn Schmiedebergs Arch. Pharmacol. 268, 33–43 (1971)Google Scholar
  234. Timmermans, P.B.U.W.U.: Clonidine (catapresanR)and structurally related imidazolines. Central hypotensive and antihypertensive activities; a structure-activity relationship study. Academische Pers., Amsterdam, 1976Google Scholar
  235. Toda, N., Fukuda, N., Shimamoto, K.: The mode of hypotensive actions of 2-(2,6-dichlor-phenyl-1-amino) imidazoline in the rabbit. Jpn. J. Pharmacol. 19, 199–210 (1969)Google Scholar
  236. Trendelenburg, U.: Supersensitivity and subsensitivity to sympathomimetic agents. Pharmacol. Rev. 15, 225–276 (1963)Google Scholar
  237. Trolin, G.: Effects of pentobarbitone and decerebration on the clonidine induced circulatory changes. Eur. J. Pharmacol. 34, 1–7 (1975)Google Scholar
  238. Ungerstedt, U.: Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol. Scand. (Suppl.) 367, 1–48 (1971)Google Scholar
  239. Uvnäs, B.: Central cardiovascular control. In: Handbook of Physiology, Section 1: Neurophysiology. Washington: American Physiological Society 1960, Vol. II, pp. 1131–1162Google Scholar
  240. Vizi, E.S., Somogyi, G.T., Hadházy, P., Knoll, J.: Effect of duration and frequency of stimulation on the presynaptic inhibition by α-adrenoceptor stimulation of the adrenergic transmission. Naunyn Schmiedebergs Arch. Pharmacol. 280, 79–91 (1973)Google Scholar
  241. Vorburger, C., Butikofer, E., Reubi, F.: Die akute Wirkung von St 155 auf die cardiale und renale Haemodynamik. In: Hochdrucktherapie. Heilmeyer, L., Holtmeier, H.-J., Pfeiffer, E.F. (eds.). Stuttgart: Georg Thieme Verlag, 1968, pp. 86–94Google Scholar
  242. Waite, R.: Inhibition of sympathetic nerve activity resulting from central alpha-adreno-ceptor stimulation. In: Recent Advances in Hypertension. Milliez, P., Safar, M. (eds.). Reims: Boehringer Ingelheim 1975, Vol. II, pp. 27–32Google Scholar
  243. Walland, A., Kobinger, W., Csongrady, A.: Action of clonidine on baroreceptor reflexes in conscious dogs. Eur. J. Pharmacol. 26, 184–190 (1974)Google Scholar
  244. Wermuth, C.G., Schwartz, J., Leclerc, G., Gamier, J.P., Rout, B.: Conformation de la clonidine et hypotheses sur son interaction avec un récepteur α-adrénergique. Chim. Thér. 1, 115–116 (1973)Google Scholar
  245. Werner, U., Starke, K., Schumann, H.J.: Actions of clonidine and 2-(2-methyl-6-ethyl-cyclohexylamino)-2-oxazoline on postganglionic autonomic nerves. Arch. Int. Pharmacodyn. 195, 282–290 (1972)Google Scholar
  246. Wing, L.M.H., Davies, D.S., Reid, J.L., Dollery, C.T.: Clonidine overdose. Br. Med. J. 4, 408–409 (1975)Google Scholar
  247. Zaimis, E., Hanington, E.: A possible pharmacological approach to migraine. Lancet 1969/II, 298–300Google Scholar
  248. van Zwieten, P.A.: Antihypertensive drugs with a central action. Prog. Pharmacol. Stuttgart: Gustav Fischer Verlag 1975, Vol. I, No. 1Google Scholar
  249. van Zwieten, P.A.: Centrally induced hypotension by 2-(2,6-dichlorphenyl)-5,6-dihy-droimidazo (2,1-b)-thiazole fumarate (compound 44-549) Pharmacology 13, 352–355Google Scholar
  250. van Zwieten, P.A.: Reduction of the hypotensive effect of clonidine and alpha-methyl-dopa by various psychotropic drugs. Clin. Sci. Molec. Med. 51, 411–413 (1976)Google Scholar
  251. van Zwieten, P.A., Pauer, M., van Spanning, H.W., DE Langen, C.: Interaction between centrally acting hypotensive drugs and tricyclic antidepressants. Arch. Int. Pharmacodyn. 214, 12–30 (1975)Google Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • Walter Kobinger
    • 1
  1. 1.Ernst Boehringer Institut fur ArzneimittelforschungWienAustria

Personalised recommendations